A068270 Stock Overview
Develops and produces drugs based on proteins for the treatment of oncology in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Celltrion, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩181,800.00 |
| 52 Week High | ₩241,000.00 |
| 52 Week Low | ₩131,000.00 |
| Beta | 0.25 |
| 11 Month Change | -2.15% |
| 3 Month Change | -6.48% |
| 1 Year Change | 22.01% |
| 33 Year Change | -27.50% |
| 5 Year Change | 33.26% |
| Change since IPO | 1,729.41% |
Recent News & Updates
Here's Why Celltrion (KRX:068270) Has A Meaningful Debt Burden
Jun 26
Estimating The Intrinsic Value Of Celltrion, Inc. (KRX:068270)
May 22Recent updates
Here's Why Celltrion (KRX:068270) Has A Meaningful Debt Burden
Jun 26Estimating The Intrinsic Value Of Celltrion, Inc. (KRX:068270)
May 22Celltrion, Inc. (KRX:068270) Not Flying Under The Radar
Apr 30Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues
Mar 25We Think Celltrion (KRX:068270) Can Stay On Top Of Its Debt
Mar 19Here's Why I Think Celltrion (KRX:068270) Is An Interesting Stock
May 05Robust Earnings May Not Tell The Whole Story For Celltrion (KRX:068270)
Mar 25Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like
Mar 15Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?
Feb 24Celltrion (KRX:068270) Has A Rock Solid Balance Sheet
Feb 03Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?
Jan 13
Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?
Dec 23Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?
Dec 02Shareholder Returns
| A068270 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -13.0% | -1.2% | -2.1% |
| 1Y | 22.0% | 28.3% | 0.3% |
Return vs Industry: A068270 underperformed the KR Biotechs industry which returned 28.3% over the past year.
Return vs Market: A068270 exceeded the KR Market which returned 0.3% over the past year.
Price Volatility
| A068270 volatility | |
|---|---|
| A068270 Average Weekly Movement | 4.3% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.2% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A068270 has not had significant price volatility in the past 3 months.
Volatility Over Time: A068270's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Hyong-Gi Kim | www.celltrion.com |
Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 that is in phase 3 clinical trial for the treatment of asthma and urticaria; CT-P41, which is in phase 3 clinical trial for the treatment of osteoporosis and bone loss; CT-P42, which is in phase 3 clinical trial for the treatment of diabetic macular edema; and CT-P43 that is in phase 3 clinical trial for the treatment of psoriasis, crohn's disease, and ulcerative colitis.
Celltrion, Inc. Fundamentals Summary
| A068270 fundamental statistics | |
|---|---|
| Market cap | ₩39.84t |
| Earnings (TTM) | ₩392.83b |
| Revenue (TTM) | ₩2.32t |
95.2x
P/E Ratio16.2x
P/S RatioIs A068270 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A068270 income statement (TTM) | |
|---|---|
| Revenue | ₩2.32t |
| Cost of Revenue | ₩1.22t |
| Gross Profit | ₩1.09t |
| Other Expenses | ₩701.54b |
| Earnings | ₩392.83b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.91k |
| Gross Margin | 47.26% |
| Net Profit Margin | 16.96% |
| Debt/Equity Ratio | 12.7% |
How did A068270 perform over the long term?
See historical performance and comparison